DGX vs IQV
Quest Diagnostics and IQVIA, both Healthcare
IQVIA is the larger company at $28B against $22B. On trailing earnings DGX is the cheaper of the two at a P/E of 27.1 against 32.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year IQV returned +47% against +44% for DGX. Ryufin's sector-relative Smart Score puts IQV ahead, 9/10 against 6/10.
| Figure | DGX | IQV |
|---|---|---|
| Last close | $245 | $262 |
| Market cap | $22B | $28B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.1 | 32.5 |
| 1-year return | +44% | +47% |
| 5-year return | +90% | +5.6% |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Quest Diagnostics
Revenue of $2.9B in Q1 2026, net income $252M. Its largest reported line is Diagnostic Information Services Business, 98% of the disclosed total.
IQVIA
Revenue of $4.2B in Q1 2026, net income $274M. Its largest reported line is Research And Development Solutions, 56% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.